Over the last decade, remarkable innovations in transcatheter technologies have led to the rapid development of an array of minimally invasive therapies that have challenged conventional treatment paradigms. Amongst these, none is as remarkable or as potentially disruptive as transcatheter aortic valve replacement (TAVR). An archetype of “bench-to-bedside” medicine, the origins of TAVR spanned the expertise of visionary clinicians to engineers to researchers to imagers. The theme underpinning the foundation of TAVR—that of a multidisciplinary approach to its development—persists in its application. From the landmark effort of Cribier who, in 2002, reported the first successful implantation of a transcatheter aortic valve, we have consistently witnessed a team approach to the execution of this complex procedure—bringing together a diverse group of experts to optimize patient outcomes. It is perhaps, in large part, due to this that we have observed an unprecedented growth in the scientific evidence, iterative technological advances, and utilization of TAVR that has surpassed even the most optimistic of observers.